Leveraging Biomedical Data to Understand and Fight Disease

Griffin Catalyst is supporting a major enhancement of UK Biobank, one of the world’s leading scientific resources for health data and biological samples. Griffin Catalyst’s $10 million gift—matched by Eric Schmidt and Schmidt Futures—will enable UK Biobank and scientists from around the world to accelerate research into disease mechanisms, to better leverage artificial intelligence, and to work towards more personalized options for treatment.
Griffin Catalyst Founder Ken Griffin speaks at an event announcing a new public-private consortium to support UK Biobank at 10 Downing Street, London, on October 30, 2023.
Photo Credit: Rory Arnold

First launched in 2006, UK Biobank has grown to be one of the largest and most thorough biomedical databases in the world, encompassing genetic, physical, and health data from 500,000 volunteers. This vast resource for health research, augmented regularly with new data, has enabled groundbreaking discovery globally into disease cause and progression.

WHO WE’RE SUPPORTING

UK Biobank’s vast trove of data is uniquely available to researchers across the world. Currently, over 30,000 researchers from more than 90 countries are registered to use UK Biobank, including 10,000 researchers in the United States alone. With its steady growth in data and with new technologies, UK Biobank is becoming the world’s preeminent biomedical database.

To achieve that goal, UK Biobank is enhancing its older infrastructure with cutting-edge equipment, including a latest-generation robotic freezer that can store and swiftly retrieve—four times faster than at present—the 20 million biological samples that have been donated by UK Biobank’s half-million volunteer participants.  At the same time, UK Biobank is accelerating its efforts to digitize tens of thousands of older medical slides associated with tumor biopsies, among other illnesses, readying these samples for Artificial Intelligence (AI).

To make room for these new initiatives, the U.K. government recently announced a £154 million investment into UK Biobank’s physical infrastructure for a purpose-built 131,000-square-foot facility in Manchester Science Park, in the heart of the city’s Oxford Road Corridor Innovation District.  Operated with the support of The University of Manchester, this new state-of-the-art facility will accommodate improved biological storage and processing laboratories and will expand access for researchers from around the country and the world.

Griffin Catalyst’s support for UK Biobank will enable essential follow-on research into how participants’ health has changed over the years and how wearable technologies impact health assessments, as well as into biomarkers for early disease detection. These collective donations to UK Biobank will allow cutting-edge AI applications to draw upon these datasets to drive new insights and discoveries into how to treat, or even prevent a wide range of disease.

With philanthropic support from Griffin Catalyst and Schmidt Futures, this public-private consortium complements the U.K. government’s investments in research and development to provide new funding pathways for the world’s most gifted researchers to take greater risks and to pursue new approaches.

WHY IT MATTERS

Far too often, doctors detect many types of serious or fatal diseases—such as pancreatic cancer—too late. By the time patients are experiencing symptoms, there are often no effective interventions.

One emerging solution is the use of biomarkers, whose discovery can enable early diagnosis of life-threatening diseases such as cancer or Alzheimer’s disease—even before patients themselves experience any symptoms.  Advances in AI can empower researchers to analyze and interpret UK Biobank’s immense data.  In one such breakthrough, in 2018, researchers analyzing genomic data from UK Biobank were able to devise a genetic test to detect people born with an increased risk of coronary heart disease, thus alerting doctors and allowing proactive measures to be carried out before life-threatening situations arise.

As it expands its work into other areas, UK Biobank will also continue its existing pioneering data collection—including the world’s largest imaging study of internal organs, which will open up new ways to investigate mechanisms for diseases as diverse as arthritis, coronary heart disease, osteoporosis, and Alzheimer’s.

WHAT’S THE IMPACT

The expansion and upgrade of UK Biobank—already recognized as a key global scientific resource—will enable it to extend its service to medicine and biology and, through improved biomarkers and other techniques, lay the groundwork for future scientific discoveries that will dramatically improve human health and treatment.

An important benefit of UK Biobank’s efforts relates to the development of new medications; biomarkers allow for shorter, less expensive clinical trials, leading companies to invest additional resources into the discovery of new drugs, and thus bring new treatments to the public more swiftly.

What no one can put a number to is the sheer human impact that the early detection of life-threatening diseases will have for patients everywhere.

Griffin Catalyst Founder Ken Griffin (far left) joined with UK Biobank Chief Scientist Naomi Allen (center left), Schmidt Futures Co-Founder Eric Schmidt (center right), and U.K. Minister of State for Science, Innovation, and Technology George Freeman (far right) to celebrate the launch of a new public-private consortium to unlock U.K. government-matching-funding in support of UK Biobank.

Photo Credit: Rory Arnold
Share

In Brief

September 8, 2023
In 2022, Griffin Catalyst joined with partners to support the Organs Initiative, a coalition leveraging data to drive change with broad bipartisan support. The challenge: To fix a broken, inefficient organ donation system that leads to tens of thousands of healthy organs going unrecovered each year and contributes to 30 Americans dying every day for lack of an available organ. In August 2022, the group achieved the first major overhaul of the organ donation system in 40 years, projected to save over 7,000 lives annually. Almost a year later, in July 2023, Congress unanimously passed legislation to break up
October 30, 2023
Griffin Catalyst is funding the construction and programming of 50 soccer mini-pitches in underserved communities across Florida’s Miami-Dade County. The $5 million initiative, carried out with The Children’s Trust, the U.S. Soccer Foundation, and Miami-Dade County, will increase access to the game for young people county-wide, impacting over 30,000 local children over the next seven years, and help build community in dozens of neighborhoods.
June 30, 2020
Griffin Catalyst has made the largest gift in the history of the Navy SEAL Foundation, to provide critical education, health care, and financial support to members of one of the U.S. military’s most elite special operations forces and their families.
February 12, 2024
The Lincoln Memorial has long been one of America’s most visited monuments and the scene of some of the defining moments of the last century. In time for the 250th anniversary of the country, a new expansion project will transform a massive, long-hidden space beneath the Lincoln Memorial on the National Mall into an immersive museum, exhibition, and theater space, encouraging visitors to explore the story of one of America’s greatest presidents, Abraham Lincoln, and to learn about the nation’s progress toward becoming a more perfect union.
December 27, 2023
The success of Operation Warp Speed in 2020, which brought forth an effective COVID-19 vaccine in less than twelve months, was not only a scientific breakthrough but also a demonstration of the power of an approach called an advanced market commitment (AMC). By creating a demand so that pharmaceutical companies could invest in production prior to proving the efficacies of vaccines, this successful approach accelerated time to market and highlighted the opportunity for a class of similar “market-shaping tools” to accelerate progress. To expand this approach, Griffin Catalyst and Schmidt Futures have partnered with the University of Chicago to launch
December 20, 2023
On ABC's Good Morning America, Anchors Robin Roberts and Lara Spencer joined with Ken Griffin, Founder and CEO of Citadel and Founder of Griffin Catalyst, and Dr. Selwyn Vickers, President and CEO of Memorial Sloan Kettering (MSK) to announce the largest donation in MSK's nearly 150-year history.
November 21, 2023
In a conversation at George Washington's Mount Vernon, Ken Griffin, Founder and CEO of Citadel and Founder of Griffin Catalyst, joined David Rubenstein, renowned investor and philanthropist, to discuss the importance of America's founding principles and constitutional government.
November 14, 2023
Griffin Catalyst is supporting a major enhancement of UK Biobank, one of the world’s leading scientific resources for health data and biological samples. Griffin Catalyst’s $10 million gift—matched by Eric Schmidt and Schmidt Futures—will enable UK Biobank and scientists from around the world to accelerate research into disease mechanisms, to better leverage artificial intelligence, and to work towards more personalized options for treatment.